Clinical Trial Update: Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating whether denosumab for bone loss in men with non-metastatic prostate cancer is associated with new or worsening lens opacifications (cat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract
• Low Bone Mineral Density
• Osteopenia
• Osteoporosis
• Prostate Cancer

Drugs mentioned

• Denosumab (denosumab)
• Xgeva (denosumab)

Snippet

Sponsor: Amgen | Conditions: Cancer, Cataract | Phase 3 | Status: COMPLETED | Results posted: 2017-05-30